Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours

Molecular Oncology

Volumn 9, Issue 2, 2015, Pages 503-512

  Ricardo, Sara ^a   Marcos Silva, Lara ^a,b,c   Pereira, Daniela ^a   Pinto, Rita ^a   Almeida, Raquel ^a,b   Söderberg, Ola ^d   Mandel, Ulla ^c   Clausen, Henrik ^c   Felix, Ana ^e,f   Lunet, Nuno ^a,b   David, Leonor ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^f UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Glyco mucin profile; MUC1; MUC16; Ovarian cancer; Proximity ligation assay

Indexed keywords

GLYCAN; GLYCOPROTEIN; MUCIN; MUCIN 1; MUCIN 16; TUMOR MARKER; UNCLASSIFIED DRUG; CA 125 ANTIGEN; ISOPROTEIN; MEMBRANE PROTEIN; MUC1 PROTEIN, HUMAN; MUC16 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER TISSUE; CONTROLLED STUDY; CYSTADENOMA; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; AGED; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; RETROSPECTIVE STUDY; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN-1; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84921309842     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.005     Document Type: Article

References (52)

1. Akita K., Yoshida S., Ikehara Y., Shirakawa S., Toda M., Inoue M., Kitawaki J., Nakanishi H., Narimatsu H., Nakada H. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int. J. Gynecol. Cancer 2012, 22:531-538.
2. Assarsson E., Lundberg M., Holmquist G., Bjorkesten J., Bucht Thorsen S., Ekman D., Eriksson A., Rennel Dickens E., Ohlsson S., Edfeldt G., Andersson A.C., Lindstedt P., Stenvang J., Gullberg M., Fredriksson S. Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PloS one 2014, 9:e95192.
3. Avninder S., Ylaya K., Hewitt S.M. Tissue microarray: a simple technology that has revolutionized research in pathology. J.Postgrad. Med. 2008, 54:158-162.
4. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., Jacques S., Malone J., Munkarah A.R. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. obstetrics Gynecol. 2003, 189:1120-1127.
5. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J.Clin. Invest. 1981, 68:1331-1337.
6. Bressan A., Bozzo F., Maggi C.A., Binaschi M. OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. Dis. Markers 2013, 34:257-267.
7. Chen K., Gentry-Maharaj A., Burnell M., Steentoft C., Marcos-Silva L., Mandel U., Jacobs I., Dawnay A., Menon U., Blixt O. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J.Proteome Res. 2013, 12:1408-1418.
8. Conze T., Carvalho A.S., Landegren U., Almeida R., Reis C.A., David L., Soderberg O. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology 2010, 20:199-206.
9. Cramer D.W., Bast R.C., Berg C.D., Diamandis E.P., Godwin A.K., Hartge P., Lokshin A.E., Lu K.H., McIntosh M.W., Mor G., Patriotis C., Pinsky P.F., Thornquist M.D., Scholler N., Skates S.J., Sluss P.M., Srivastava S., Ward D.C., Zhang Z., Zhu C.S., Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. 2011, 4:365-374.
10. Curry E.W., Stronach E.A., Rama N.R., Wang Y.Y., Gabra H., El-Bahrawy M.A. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures. Mod. Pathol. 2014, 27:433-442.
11. Darmanis S., Nong R.Y., Hammond M., Gu J., Alderborn A., Vanelid J., Siegbahn A., Gustafsdottir S., Ericsson O., Landegren U., Kamali-Moghaddam M. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol. Cell. Proteomics 2010, 9:327-335.
12. Davidson B., Berner A., Nesland J.M., Risberg B., Kristensen G.B., Trope C.G., Bryne M. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 2000, 31:1081-1087.
13. De Angelis R., Sant M., Coleman M.P., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., Bielska-Lasota M., Engholm G., Nennecke A., Siesling S., Berrino F., Capocaccia R., Group E.-W. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014, 15:23-34.
14. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2012, [Internet], International Agency for Research on Cancer, Lyon, France, 2013. Available from:, (accessed on day/month/year). http://globocan.iarc.fr.
15. Fredriksson S., Gullberg M., Jarvius J., Olsson C., Pietras K., Gústafsdóttir S.M., Ostman A., Landegren U. Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 2002, 20:473-477.
16. Fredriksson S., Horecka J., Brustugun O.T., Schlingemann J., Koong A.C., Tibshirani R., Davis R.W. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin. Chem. 2008, 54:582-589.
17. Ghazizadeh M., Ogawa H., Sasaki Y., Araki T., Aihara K. Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Hum. Pathol. 1997, 28:960-966.
18. Gill D.J., Clausen H., Bard F. Location, location, location: new insights into O-GalNAc protein glycosylation. Trends Cell Biol. 2011, 21:149-158.
19. Gipson I.K. Distribution of mucins at the ocular surface. Exp. Eye Res. 2004, 78:379-388.
20. Goonewardene T.I., Hall M.R., Rustin G.J. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007, 8:813-821.
21. Gullberg M., Gustafsdottir S.M., Schallmeiner E., Jarvius J., Bjarnegard M., Betsholtz C., Landegren U., Fredriksson S. Cytokine detection by antibody-based proximity ligation. Proc. Natl. Acad. Sci. USA. 2004, 101:8420-8424.
22. Haridas D., Chakraborty S., Ponnusamy M.P., Lakshmanan I., Rachagani S., Cruz E., Kumar S., Das S., Lele S.M., Anderson J.M., Wittel U.A., Hollingsworth M.A., Batra S.K. Pathobiological implications of MUC16 expression in pancreatic cancer. PloS one 2011, 6:e26839.
23. Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70:431-457.
24. Hirabayashi Y., Marugame T. Comparison of time trends in ovary cancer mortality (1990-2006) in the world, from the WHO Mortality Database. Jpn. J. Clin. Oncol. 2009, 39:860-861.
25. Jabbar K.S., Verbeke C., Hyltander A.G., Sjovall H., Hansson G.C., Sadik R. Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. J.Natl. Cancer Inst. 2014, 106:djt439.
26. Jacobs I., Bast R.C. The Ca-125 tumor-associated antigen - a review of the Literature. Hum. Reprod. 1989, 4:1-12.
27. Karlan B.Y., Thorpe J.D., Watabayashi K., Drescher C.W., Palomares M.R., Daly M., Paley P.J., Hillard P.J., Andersen M.R., Anderson G.L., Drapkin R., Urban N. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol. Biomarkers Prev. 2014, 23:1383-1393.
28. Kim J.H., Park C.W., Um D., Baek K.H., Jo Y., An H., Kim Y., Kim T.J. Mass spectrometric screening of ovarian cancer with serum glycans. Dis. Markers 2014, 2014:634289.
29. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2---6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988, 48:2214-2220.
30. Kondalsamy-Chennakesavan S., Hackethal A., Bowtell D., Obermair A. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol. Oncol. 2013, 129:467-471. Australian Ovarian Cancer Study, G.
31. Kui Wong N., Easton R.L., Panico M., Sutton-Smith M., Morrison J.C., Lattanzio F.A., Morris H.R., Clark G.F., Dell A., Patankar M.S. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J.Biol. Chem. 2003, 278:28619-28634.
32. Lin W., Du Y., Zhu Y., Chen X. A cis-membrane FRET-based method for protein-specific imaging of cell-surface glycans. J.Am. Chem. Soc. 2014, 136:679-687.
33. Mai P.L., Wentzensen N., Greene M.H. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev. Res. 2011, 4:303-306.
34. Mandel U., Petersen O.W., Sorensen H., Vedtofte P., Hakomori S., Clausen H., Dabelsteen E. Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J.Invest. Dermatol. 1991, 97:713-721.
35. Marcos-Silva L., Narimatsu Y., Halim A., Campos D., Yang Z., Tarp M.A., Pereira P.J., Mandel U., Bennett E.P., Vakhrushev S.Y., Levery S.B., David L., Clausen H. Characterization of binding epitopes of CA125 monoclonal antibodies. J.Proteome Res. 2014, 13:3349-3359.
36. Moore R.G., Jabre-Raughley M., Brown A.K., Robison K.M., Miller M.C., Allard W.J., Kurman R.J., Bast R.C., Skates S.J. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am. J. Obstet. Gynecol. 2010, 203(228):e221-226.
37. Nustad K., Bast R.C., Brien T.J., Nilsson O., Seguin P., Suresh M.R., Saga T., Nozawa S., Bormer O.P., de Bruijn H.W., Nap M., Vitali A., Gadnell M., Clark J., Shigemasa K., Karlsson B., Kreutz F.T., Jette D., Sakahara H., Endo K., Paus E., Warren D., Hammarstrom S., Kenemans P., Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol. 1996, 17:196-219.
38. Pinto R., Carvalho A.S., Conze T., Magalhaes A., Picco G., Burchell J.M., Taylor-Papadimitriou J., Reis C.A., Almeida R., Mandel U., Clausen H., Soderberg O., David L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J.Cell. Mol. Med. 2012, 16:1474-1484.
39. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012, 460:237-249.
40. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004, 23:41-44.
41. Simon R., Mirlacher M., Sauter G. Tissue microarrays. Methods Mol. Med. 2004, 97:377-389.
42. Singh A.P., Senapati S., Ponnusamy M.P., Jain M., Lele S.M., Davis J.S., Remmenga S., Batra S.K. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008, 9:1076-1085.
43. Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., de Bruijn H.W., van der Zee A.G., Woolas R.P., Jacobs I.J., Zhang Z., Bast R.C. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J.Clin. Oncol. 2004, 22:4059-4066.
44. Soderberg O., Gullberg M., Jarvius M., Ridderstrale K., Leuchowius K.J., Jarvius J., Wester K., Hydbring P., Bahram F., Larsson L.G., Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 2006, 3:995-1000.
45. Steentoft C., Vakhrushev S.Y., Joshi H.J., Kong Y., Vester-Christensen M.B., Schjoldager K.T., Lavrsen K., Dabelsteen S., Pedersen N.B., Marcos-Silva L., Gupta R., Bennett E.P., Mandel U., Brunak S., Wandall H.H., Levery S.B., Clausen H. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 2013, 32:1478-1488.
46. Stiekema A., Lok C.A., Kenter G.G., van Driel W.J., Vincent A.D., Korse C.M. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. Gynecol. Oncol. 2014, 132:573-577.
47. Tavoosidana G., Ronquist G., Darmanis S., Yan J., Carlsson L., Wu D., Conze T., Ek P., Semjonow A., Eltze E., Larsson A., Landegren U.D., Kamali-Moghaddam M. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. USA. 2011, 108:8809-8814.
48. Taylor-Papadimitriou J., Peterson J.A., Arklie J., Burchell J., Ceriani R.L., Bodmer W.F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int. J. Cancer J. Int. du Cancer 1981, 28:17-21.
49. Van Gorp T., Cadron I., Despierre E., Daemen A., Leunen K., Amant F., Timmerman D., De Moor B., Vergote I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br. J. Cancer 2011, 104:863-870.
50. Weibrecht I., Leuchowius K.J., Clausson C.M., Conze T., Jarvius M., Howell W.M., Kamali-Moghaddam M., Soderberg O. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev. Proteomics 2010, 7:401-409.
51. Zen K., Notarfrancesco K., Oorschot V., Slot J.W., Fisher A.B., Shuman H. Generation and characterization of monoclonal antibodies to alveolar type II cell lamellar body membrane. Am. J. Physiol. 1998, 275:L172-L183.
52. Zhu C.S., Pinsky P.F., Cramer D.W., Ransohoff D.F., Hartge P., Pfeiffer R.M., Urban N., Mor G., Bast R.C., Moore L.E., Lokshin A.E., McIntosh M.W., Skates S.J., Vitonis A., Zhang Z., Ward D.C., Symanowski J.T., Lomakin A., Fung E.T., Sluss P.M., Scholler N., Lu K.H., Marrangoni A.M., Patriotis C., Srivastava S., Buys S.S., Berg C.D., Team P.P. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res. 2011, 4:375-383.